OncoCyte (OCX)
(Real Time Quote from BATS)
$3.24 USD
+0.07 (2.21%)
Updated Jul 23, 2024 03:43 PM ET
After-Market: $3.22 -0.02 (-0.62%) 4:18 PM ET
2-Buy of 5 2
F Value F Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
OCX 3.24 +0.07(2.21%)
Will OCX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for OCX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for OCX
CareDx (CDNA) Reports Q2 Loss, Tops Revenue Estimates
Surgery Partners (SGRY) Q1 Earnings and Revenues Beat Estimates
OCX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Elevance Health (ELV) Tops Q1 Earnings and Revenue Estimates
3 Medical Services Stocks to Buy Amid Industry Challenges
Life Time Group Holdings, Inc. (LTH) Tops Q4 Earnings and Revenue Estimates
Other News for OCX
MedTech Gurus Podcast Features Oncocyte CEO Josh Riggs in "Take Advantage of the Moment" Episode
Oncocyte Bolsters Executive Team with Key CFO Appointment: PRISM MarketView Highlights Strategic Leadership Move
Oncocyte Appoints Andrea James as Chief Financial Officer
OncoCyte Announces Andrea James as New CFO and Principal Officer
OncoCyte appoints CFO